middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
acut
respiratori
ill
fever
cough
short
breath
date
result
human
infect
includ
death
analog
picornaviru
proteas
pro
proteas
pro
critic
initi
merscov
replic
cycl
thu
regard
valid
drug
target
present
peptidomimet
inhibitor
enteroviru
pro
inhibit
pro
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
ic
valu
rang
mm
mm
respect
merscovinfect
cell
inhibitor
show
antivir
activ
ec
valu
rang
mm
downregul
viral
protein
product
cell
well
reduc
secret
infecti
viral
particl
cultur
supernat
also
suppress
aand
bcov
human
felin
origin
compound
exhibit
good
select
index
merscov
could
lead
develop
broadspectrum
antivir
drug
emerg
cov
picornavirus
coronavirus
cov
affect
upper
respiratori
tract
first
identifi
human
tyrrel
byno
late
emerg
life
threaten
cov
atyp
pneumonia
name
sever
acut
respiratori
syndrom
cov
sarscov
sarscov
belong
famili
coronavirida
envelop
positivestrand
rna
viru
nucleotid
rota
et
al
genom
encod
two
polyprotein
kda
kda
process
proteas
pro
papainlik
proteas
pl
pro
gener
nonstructur
protein
essenti
viral
replic
thiel
et
al
thiel
et
al
due
vital
role
replic
pro
regard
valid
drug
target
mani
inhibitor
sarscov
pro
discov
high
throughput
screen
structurebas
ration
design
summar
review
articl
hilgenfeld
peiri
kumar
et
al
kuo
liang
pillaiyar
et
al
ramajayam
et
al
tong
zhao
et
al
sarscov
infect
subsid
middl
east
respiratori
syndrom
cov
merscov
emerg
saudi
arabia
spread
worldwid
kill
report
patient
http
wwwwhointmediacentrefactsheetsmerscov
en
due
similar
matur
pathway
merscov
pro
also
regard
target
develop
antivir
drug
though
tremend
effort
made
develop
inhibitor
therapeut
intervent
continu
cov
outbreak
yet
reach
market
barnard
kumaki
kilianski
baker
cov
pro
function
similar
pro
picornavirus
adopt
chymotrypsin
fold
howev
pro
dimer
cyshi
dyad
wherea
pro
monom
cyshisglu
triad
hsu
et
al
lee
et
al
yang
et
al
picornavirus
small
nonenvelop
rna
viru
genom
size
nucleotid
base
genet
organ
famili
compos
genera
includ
enteroviru
enteroviru
rhinoviru
aphthoviru
footandmouth
diseas
viru
cardioviru
encephalomyocard
viru
hepatoviru
hepat
viru
other
http
wwwpicornaviridaecom
pro
produc
genera
picornavirida
viru
famili
inhibitor
show
broadspectrum
potent
antivir
activ
rhinoviru
coxsackieviru
enteroviru
jetsadawisut
et
al
kim
et
al
st
john
et
al
though
pro
pro
share
similar
structur
activ
site
subtl
differ
often
discrimin
inhibitor
establish
pro
inhibitor
inact
sarscov
pro
prior
modif
ghosh
et
al
shie
et
al
thanigaimalai
et
al
yang
et
al
unlik
contain
bunsatur
ester
form
coval
bond
activesit
cy
previous
report
potent
peptidomimet
inhibitor
pro
enteroviru
contain
aldehyd
electrophil
warhead
kuo
et
al
work
screen
pro
inhibitor
merscov
pro
evalu
hit
cellbas
assay
use
live
merscov
best
compound
inhibit
merscov
pro
ic
valu
rang
mm
also
suppress
viral
replic
ec
valu
mm
deriv
repres
cellbas
assayconfirm
antimerscov
agent
also
show
broadspectrum
activ
aand
btype
cov
describ
herein
compound
report
synthes
use
previous
report
procedur
modif
kuo
et
al
test
compound
gemcitabin
hydrochlorid
gem
sigmaaldrich
st
loui
mo
dissolv
dimethyl
sulfoxid
dmso
sigmaaldrich
mm
concentr
gibco
brl
grand
island
ny
supplement
fetal
bovin
serum
fb
gibco
brl
c
co
minim
adapt
mutat
probabl
merscov
anoth
speci
passag
merscov
amplifi
infect
human
cell
line
cell
infecti
viral
titer
cultur
supernat
day
postinfect
pi
measur
plaqu
assay
use
vero
cell
accord
report
chan
et
al
de
wild
et
al
express
purif
sarscov
pro
follow
report
procedur
kuo
et
al
express
merscov
pro
kumar
et
al
factor
xa
cleavag
site
iegr
pro
access
dna
sequenc
synthes
clone
express
vector
mission
biotech
compani
taiwan
transform
e
coli
ml
overnight
cultur
singl
transform
use
inocul
fresh
lb
medium
contain
mgml
ampicillin
cell
grown
c
induc
mm
isopropylbthiogalactopyranosid
iptg
h
c
cell
harvest
centrifug
g
min
pellet
suspend
lysi
buffer
mm
trishcl
mm
nacl
mm
edta
mm
dtt
ph
frenchpress
instrument
constant
cell
disrupt
system
use
disrupt
cell
psi
centrifug
g
h
discard
debri
cellfre
extract
load
onto
ninta
column
equilibr
lysi
buffer
contain
mm
imidazol
exhaust
wash
lysi
buffer
imidazol
concentr
wash
buffer
increas
mm
protein
elut
lysi
buffer
contain
mm
imidazol
dialyz
lysi
buffer
remov
imidazol
factor
xa
ad
final
concentr
ww
incub
c
h
remov
histag
subsequ
process
merscov
pro
pass
ninta
column
purif
protein
concentr
determin
protein
assay
kit
biorad
usa
bsa
use
standard
fluorometr
assay
use
fluorogen
peptid
dabcylktsavlqsgfrkmeedan
previous
describ
kuo
et
al
use
determin
inhibit
constant
compound
enhanc
fluoresc
due
cleavag
substrat
catalyz
pro
monitor
nm
excit
nm
ic
valu
individu
sampl
measur
reaction
mixtur
contain
nm
sarscov
pro
mm
merscov
pro
mm
fluorogen
substrat
mm
bistri
ph
cell
seed
plate
cell
per
well
next
day
cell
infect
merscov
multipl
infect
moi
dmem
without
fb
h
wash
pb
mockinfect
virusinfect
cell
treat
serial
dilut
test
compound
gem
use
posit
control
day
pi
cell
lysat
harvest
measur
cell
viabil
use
celltit
aq
ueou
one
solut
cell
prolifer
assay
accord
manufactur
instruct
promega
madison
wi
cytotox
concentr
cc
effect
concentr
ec
valu
calcul
use
graphpad
prism
softwar
graphpad
softwar
la
jolla
ca
antivir
assay
cov
includ
fipv
strain
perform
mention
use
differ
cell
line
cell
use
cultur
human
cov
crfk
cell
felin
cov
fipv
cell
seed
plate
cell
per
well
infect
merscov
moi
h
wash
pb
cell
treat
mm
compound
parallel
dmso
treat
compound
vehicl
day
pi
mg
cell
lysat
suspend
sampl
load
buffer
biosesang
gyeonggido
republ
korea
subject
sdspage
electrotransf
polyvinyliden
fluorid
membran
millipor
billerica
merscov
np
detect
use
primari
antibodi
specif
viral
nucleocapsid
protein
np
cat
sino
biolog
inc
beij
china
follow
horseradish
peroxidas
hrp
conjug
goat
antirabbit
secondari
antibodi
thermo
scientif
waltham
cellular
bactin
protein
load
control
detect
antibactinspecif
primari
antibodi
cat
sigmaaldrich
hrpconjug
goat
antimous
secondari
antibodi
thermo
scientif
addit
chemiluminesc
hrp
substrat
supersign
west
pico
chemiluminesc
substrat
pierc
rockford
il
imag
obtain
use
luminesc
imag
analyz
fujifilm
tokyo
japan
cell
inocul
plate
densiti
cell
per
well
day
cultur
supernat
treat
mm
compound
harvest
day
pi
serial
dilut
dmem
ml
sampl
use
infect
vero
cell
h
wash
pb
remov
unabsorb
viru
dmem
contain
agaros
overlay
medium
ad
day
pi
plaqu
visual
mgml
neutral
red
sigmaaldrich
inhibit
merscov
pro
viral
infect
peptidomimet
compound
synthes
accord
report
method
kuo
et
al
preliminari
screen
peptidomimet
compound
mer
pro
done
mm
compound
inhibit
half
proteas
activ
condit
select
ic
measur
use
enzymat
assay
compound
show
ic
mm
purifi
pro
merscov
respect
tabl
compound
also
inhibit
sar
pro
lower
ic
valu
mm
respect
evalu
abil
compound
block
viral
replic
perform
cytopath
inhibit
assay
use
merscovinfect
cell
shown
fig
compound
effici
suppress
viral
replic
ec
mm
respect
tabl
though
usual
see
ec
higher
ic
due
presenc
membran
barrier
observ
ec
smaller
ic
could
due
higher
concentr
nm
use
invitro
enzymat
assay
weakli
associ
dimer
fact
inhibit
nm
sar
pro
tight
dimer
submicromolar
rang
tabl
compound
cc
larger
mm
mm
uninfect
cell
result
select
index
si
valu
larger
expect
compound
inact
enzym
assay
suppress
viral
replic
gem
use
posit
control
accord
previou
report
dyall
et
al
less
potent
inhibit
merscov
infect
ec
valu
mm
also
show
margin
toxic
thu
decreas
viabil
mock
cell
concentr
mm
tabl
fig
confirm
observ
antivir
activ
compound
reflect
inhibit
merscov
infect
viral
protein
progeni
product
measur
treatment
virusinfect
cell
compound
western
blot
analysi
show
viral
np
decreas
inhibitor
dosedepend
manner
fig
noteworthi
viral
np
detect
presenc
mm
pro
inhibitor
compar
number
infecti
merscov
particl
cultur
supernat
presenc
absenc
pro
inhibitor
plaqu
assay
show
viral
titer
absenc
compound
plaqu
form
unit
pfu
ml
reduc
pfuml
mm
compound
respect
fig
taken
togeth
result
suggest
compound
origin
select
pro
blocker
effici
inhibit
merscov
pro
activ
suppress
viral
protein
product
well
viral
progeni
gener
data
also
indic
inhibitor
penetr
virusinfect
cell
membran
reach
activ
site
pro
ration
potent
inhibit
dock
activ
site
merscov
pro
initi
pose
complex
gener
base
xray
structur
pdb
code
pro
complex
coval
inhibitor
human
rhinoviru
pro
bound
irrevers
inhibitor
matthew
et
al
webber
et
al
simul
done
discoveri
studio
accelri
inc
san
diego
ca
cy
subsit
pro
act
nucleophil
cleav
substrat
attack
carbonyl
carbon
amid
bond
conserv
gln
small
amino
acid
ser
ala
gli
fan
et
al
needl
et
al
model
show
gsulfur
form
coval
bond
aldehyd
carbon
result
oxyanion
stabil
fig
cyclic
lactam
moieti
cisamid
geometri
fig
antivir
activ
merscov
cell
cell
plate
mockinfect
infect
merscov
moi
h
c
wash
pb
cell
treat
serial
dilut
test
compound
control
compound
gem
day
pi
cell
lysat
harvest
measur
cell
viabil
data
repres
mean
standard
deviat
three
independ
experi
fig
inhibit
merscov
np
product
dosedepend
manner
cell
plate
infect
merscov
moi
h
cthe
virusinfect
cell
treat
increas
concentr
mm
compound
cotreat
interferonalpha
ifn
ngml
ribavirin
rbv
mm
use
posit
control
day
pi
cell
harvest
load
sdspage
mg
per
well
immunoblot
perform
use
rabbit
antinp
antibodi
hrpconjug
goat
antirabbit
secondari
antibodi
bactin
use
load
control
bind
pro
propos
mimic
gln
peptid
substrat
matthew
et
al
base
dock
result
lactam
moieti
bind
subsit
pro
form
hbond
phenylalanin
moieti
prefer
occupi
subsit
cinnamoyl
group
occupi
may
extend
amid
group
phenylalanin
cinnamoyl
group
form
hbond
also
dock
base
apoform
merscov
pro
structur
pdb
code
ho
et
al
sinc
freeform
ligandbound
structur
show
signific
differ
activ
site
bind
mode
two
structur
inde
similar
data
shown
experiment
well
model
result
substitu
cinnamoyl
group
peptidomimet
inhibitor
seem
critic
activ
substitu
pchloro
make
halogen
bond
lead
better
potenc
compound
slightli
bulkier
mbromo
pdimethylamino
moieti
respect
display
approxim
drop
ic
compound
bulkiest
substitu
fail
inhibit
pro
even
mm
compound
lack
aldehyd
warhead
fail
inhibit
pro
emphas
import
reactiv
aldehyd
electrophil
investig
broad
spectrum
activ
three
compound
test
human
felin
cov
result
show
acov
human
strain
fipv
bcov
human
strain
sensit
compound
ec
mm
tabl
suggest
potent
broadspectrum
antivir
activ
pro
inhibitor
cc
valu
measur
use
crfk
cell
use
cultiv
human
felin
cov
respect
found
mm
therefor
si
valu
rang
shown
parenthes
peptid
peptidomimet
aldehyd
inhibitor
pro
report
akaji
et
al
akaji
et
al
zhu
et
al
test
live
cov
howev
potent
sarscov
pro
peptidomimet
aldehyd
inhibitor
shown
block
sarscov
human
cov
replic
yang
et
al
shown
studi
identifi
potent
membraneperm
merscov
inhibitor
use
live
merscov
viru
ec
mm
si
compound
ic
mm
pro
kuo
et
al
inhibit
pro
merscov
ic
mm
sarscov
ic
mm
moreov
found
inhibitor
activ
virus
includ
aand
bcov
ec
mm
less
potent
higher
ec
kill
human
bcov
although
potent
inhibit
picornaviru
ec
nm
respect
kuo
et
al
potent
inhibitor
live
merscov
identifi
far
inhibitori
activ
picornavirus
cov
make
compound
broadspectrum
antivir
agent
escal
cost
drug
discoveri
develop
antivir
agent
broadspectrum
activ
might
help
overcom
financi
hurdl
compound
synthes
lead
optim
anim
studi
need
conduct
develop
one
potent
inhibitor
antivir
drug
merscovinfect
cell
plate
treat
mm
day
cultur
supernat
harvest
serial
dilut
dmem
fresh
vero
cell
plate
infect
dilut
cell
cultur
inoculum
h
number
infecti
viral
particl
count
addit
overlay
medium
day
neutral
red
stain
fig
dock
inhibitor
merscov
pro
proteas
make
coval
bond
carbonyl
carbon
inhibitor
aldehyd
form
stabl
tetrahedr
speci
inset
result
oxyanion
stabil
proteas
shown
chargepotenti
surfac
put
substratebind
subsit
indic
moreov
possibl
hydrogen
bond
proteas
drawn
dash
line
